The Biologics Prescribers Collaborative aims to ensure that sound policies are in place to promote the safest possible use of all biologics, including biosimilars, for all patients.

About Us

As groups representing physicians who regularly prescribe biologics, we have a unique and important perspective about the use of these medicines. While biosimilars hold tremendous promise to increase access and affordability of these advanced medicines, their availability will increase the complexity of the treatment landscape. As such, the Biologics Prescribers Collaborative aims to ensure that sound policies are in place to promote the safest possible use of all biologics, including biosimilars, for all patients.

More About Us

Our Guiding Principles 

The Biologics Prescribers Collaborative’s mission is to ensure that physicians who prescribe complex biologic treatments are given a voice in discussions shaping policies that govern the use of biosimilars. Learn more about our four guiding principles and how we plan to achieve a unified prescriber voice.

Read Our Principles

Resources

View All ›

September 11, 2017

Physician Groups Comment on Biosimilar Reimbursement: Urge CMS to Adopt Unique Billing Codes

BPC urged CMS to revise their current payment policy for biosimilars by adopting unique HCPCS billing codes otherwise known as J-codes. BPC and member groups call for CMS to not take a generic approach for biosimilars medicines that are, according to scientific fact, not identical to their reference products as generics are. The groups support CMS’ intent to create competition in the market, but believe that different reimbursement levels for different biosimilars will go beyond promoting competition and will help to create a more robust market while protecting patient safety. Read More ›

September 11, 2017

Physician Groups Urge CMS to Adopt Unique Billing Codes for Biosimilar Reimbursement Policy

On September 11th, 2017, BPC and five other physician groups urged the CMS to revise their current payment policy for biosimilars by adopting unique HCPCS billing codes otherwise known as J-codes. The groups – Alliance for Patient Access, American Association of Clinical Endocrinologists, American College of Rheumatology, American Gastroenterological Association, Biologics Prescribers Collaborative and the Coalition of State Rheumatology Organizations – support CMS’ intent to create competition in the market, but believe that different reimbursement levels for different biosimilars will go beyond promoting competition and will help to create a more robust market while protecting patient safety. Read More ›

May 19, 2017

Physician Groups Comment on FDA Interchangeability Guidance: Urge for Robust Data

BPC thanks FDA for its thoughtful draft guidance “Considerations in Demonstrating Interchangeability with a Reference Product" and submitted a comment providing our perspective. When final, the guidance will provide important scientific information for manufacturers to consider when seeking licensure for proposed interchangeable products. Once available, it is critical that we, as prescribers, have all of the information we need to make informed decisions with our patients.  Read More ›

Stay Informed

Stay updated! For more information about the Biologics Prescribers Collaborative, please fill out the following information.